Kamen Dimitrov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kamen Dimitrov has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Zimpfer
Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, 1090 Vienna, Austria
7 shared publications - Thomas Schlöglhofer
Department of Cardiac and Thoracic Aortic Surgery Medical University of Vienna Vienna Austria
6 shared publications - Julia Riebandt
Department of Cardiac Surgery, Medical University of Vienna, 1090 Vienna, Austria
5 shared publications Alexandra Kaider
Institute of Clinical Biometrics, Center for Medical Data Science Medical University of Vienna Vienna Austria
4 shared publications- Dominik Wiedemann
Karl Landsteiner University of Health Sciences , Dr. Karl-Dorrek-Straße 30, Krems 3500
4 shared publications - Philipp Angleitner
Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria
4 shared publications
Latest Publications
- Open Access
- 6 August 2024
- Published by Wiley in Artificial Organs
- Vol. 48 (12) , 1513-1524
The utility of temporal trends of blood biomarkers as predictors for bloodstream infections in left ventricular assist device recipients
Background: Temporal trends of routinely obtained parameters may provide valuable information for predicting BSIs, but this association has not yet been established in LVAD patients.Methods: This retrospective analysis included data from 347 consecutive recipients of three rotary LVAD types. Study endpoints included the incidence of BSI, the association of temporal trends of routinely obtained blood biomarkers with the development of BSIs, the incidence of BSIs, and survival on LVAD support.Results: During follow‐up, 47.8% (n = 166) of the patients developed BSI. In multivariate analyses, the development of BSI was a significant predictor of mortality (HR 5.78, 95% CI 4.08–8.19, p < 0.0001). In univariate analyses, after adjusting for potential confounders, albumin (SHR 0.94, 95% CI 0.91–0.97, p < 0.00010), creatinine (SHR 1.49, 95% CI 1.03–2.15, p = 0.033), and C‐reactive protein (SHR 1.19, 95% CI 1.08–1.32, p = 0.0007) significantly predicted the development of BSIs during LVAD support. Notably, the strength of the association of parameter changes with the prediction of BSIs demonstrated a time‐dependent correlation in the cases of albumin (p = 0.045) and creatinine (p = 0.003).Conclusion: Bloodstream infections are highly prevalent among LVAD recipients and are independent predictors of mortality. Temporal biomarker trends significantly predict the development of BSIs. These findings suggest opportunities for interventions aiming to reduce the incidence of BSIs.
- 6 August 2024
- Published by Wiley in Artificial Organs
- Vol. 48 (12) , 1513-1524
Open AccessThe utility of temporal trends of blood biomarkers as predictors for bloodstream infections in left ventricular assist device recipients
Background: Temporal trends of routinely obtained parameters may provide valuable information for predicting BSIs, but this association has not yet been established in LVAD patients.Methods: This retrospective analysis included data from 347 consecutive recipients of three rotary LVAD types. Study endpoints included the incidence of BSI, the association of temporal trends of routinely obtained blood biomarkers with the development of BSIs, the incidence of BSIs, and survival on LVAD support.Results: During follow‐up, 47.8% (n = 166) of the patients developed BSI. In multivariate analyses, the development of BSI was a significant predictor of mortality (HR 5.78, 95% CI 4.08–8.19, p < 0.0001). In univariate analyses, after adjusting for potential confounders, albumin (SHR 0.94, 95% CI 0.91–0.97, p < 0.00010), creatinine (SHR 1.49, 95% CI 1.03–2.15, p = 0.033), and C‐reactive protein (SHR 1.19, 95% CI 1.08–1.32, p = 0.0007) significantly predicted the development of BSIs during LVAD support. Notably, the strength of the association of parameter changes with the prediction of BSIs demonstrated a time‐dependent correlation in the cases of albumin (p = 0.045) and creatinine (p = 0.003).Conclusion: Bloodstream infections are highly prevalent among LVAD recipients and are independent predictors of mortality. Temporal biomarker trends significantly predict the development of BSIs. These findings suggest opportunities for interventions aiming to reduce the incidence of BSIs.
- Open Access
- 6 August 2024
- Published by Wiley in Artificial Organs
- Vol. 48 (12) , 1502-1512
Preoperative anatomical landmarks and longitudinal HeartMate 3 pump position in X‐rays: Relevance for adverse events
Background: Left ventricular assist device (LVAD) malposition has been linked to hemocompatibility‐related adverse events (HRAEs). This study aimed to identify preoperative anatomical landmarks and postoperative pump position, associated with HRAEs during LVAD support.Methods: Pre‐ and postoperative chest X‐ray measures (≤14 days pre‐implantation, first postoperative standing, 6, 12, 18, and 24 months post‐implantation) were analyzed for their association with HRAEs over 24 months in 33 HeartMate 3 (HM3) patients (15.2% female, age 66 (9.5) years).Results: HM3 patients with any HRAE showed significantly lower preoperative distances between left ventricle and thoracic outline (dLVT) (25.3 ± 10.2 mm vs. 40.3 ± 15.5 mm, p = 0.004). A ROC‐derived cutoff dLVT ≤ 29.2 mm provided 85.7% sensitivity and 72.2% specificity predicting any HRAE during HM3 support (76.2% (>29.2 mm) vs. 16.7% (≤29.2 mm) freedom from HRAE, p < 0.001) and significant differences in cardiothoracic ratio (0.58 ± 0.04 vs. 0.62 ± 0.04, p = 0.045). Postoperative X‐rays indicated lower pump depths in patients with ischemic strokes (9.1 ± 16.2 mm vs. 38.0 ± 18.5 mm, p = 0.007), reduced freedom from any neurological event (pump depth ≤ 28.7 mm: 45.5% vs. 94.1%, p = 0.004), and a significant correlation between pump depth and inflow cannula angle (r = 0.66, p < 0.001). Longitudinal changes were observed in heart‐pump width (F(4,60) = 5.61, p < 0.001).Conclusion: Preoperative X‐ray markers are associated with postoperative HRAE occurrence. Applying this knowledge in clinical practice may enhance risk stratification, guide therapy optimization, and improve HM3 recipient management.
- 6 August 2024
- Published by Wiley in Artificial Organs
- Vol. 48 (12) , 1502-1512
Open AccessPreoperative anatomical landmarks and longitudinal HeartMate 3 pump position in X‐rays: Relevance for adverse events
Background: Left ventricular assist device (LVAD) malposition has been linked to hemocompatibility‐related adverse events (HRAEs). This study aimed to identify preoperative anatomical landmarks and postoperative pump position, associated with HRAEs during LVAD support.Methods: Pre‐ and postoperative chest X‐ray measures (≤14 days pre‐implantation, first postoperative standing, 6, 12, 18, and 24 months post‐implantation) were analyzed for their association with HRAEs over 24 months in 33 HeartMate 3 (HM3) patients (15.2% female, age 66 (9.5) years).Results: HM3 patients with any HRAE showed significantly lower preoperative distances between left ventricle and thoracic outline (dLVT) (25.3 ± 10.2 mm vs. 40.3 ± 15.5 mm, p = 0.004). A ROC‐derived cutoff dLVT ≤ 29.2 mm provided 85.7% sensitivity and 72.2% specificity predicting any HRAE during HM3 support (76.2% (>29.2 mm) vs. 16.7% (≤29.2 mm) freedom from HRAE, p < 0.001) and significant differences in cardiothoracic ratio (0.58 ± 0.04 vs. 0.62 ± 0.04, p = 0.045). Postoperative X‐rays indicated lower pump depths in patients with ischemic strokes (9.1 ± 16.2 mm vs. 38.0 ± 18.5 mm, p = 0.007), reduced freedom from any neurological event (pump depth ≤ 28.7 mm: 45.5% vs. 94.1%, p = 0.004), and a significant correlation between pump depth and inflow cannula angle (r = 0.66, p < 0.001). Longitudinal changes were observed in heart‐pump width (F(4,60) = 5.61, p < 0.001).Conclusion: Preoperative X‐ray markers are associated with postoperative HRAE occurrence. Applying this knowledge in clinical practice may enhance risk stratification, guide therapy optimization, and improve HM3 recipient management.
- Open Access
- 18 April 2024
- Published by IntechOpen
Exploring Standard and Alternative Sites for Left Ventricular Assist Device Inflow Cannula and Outflow Graft Placement
Left ventricular assist device (LVAD) therapy is an essential tool in the armamentarium for managing refractory heart failure. The traditional LVAD placement involves insertion of the inflow cannula (IC) at the left ventricle’s true apex and attachment of the outflow graft (OG) to the ascending aorta (AA), which ensures alignment with physiological blood flow and minimizes complications. However, patient-specific anatomical variations and prior medical interventions necessitate considering alternative IC and OG placement techniques. This chapter reviews the standard and alternative IC and OG placement sites and emphasizes the importance of adapting LVAD component placement to individual patient needs, highlighting the potential of alternative techniques in improving outcomes. Despite the predominance of standard sites due to their proven efficacy, the heterogeneity of patient conditions underscores the need for flexible, patient-tailored approaches.
- 18 April 2024
- Published by IntechOpen
Open AccessExploring Standard and Alternative Sites for Left Ventricular Assist Device Inflow Cannula and Outflow Graft Placement
Left ventricular assist device (LVAD) therapy is an essential tool in the armamentarium for managing refractory heart failure. The traditional LVAD placement involves insertion of the inflow cannula (IC) at the left ventricle’s true apex and attachment of the outflow graft (OG) to the ascending aorta (AA), which ensures alignment with physiological blood flow and minimizes complications. However, patient-specific anatomical variations and prior medical interventions necessitate considering alternative IC and OG placement techniques. This chapter reviews the standard and alternative IC and OG placement sites and emphasizes the importance of adapting LVAD component placement to individual patient needs, highlighting the potential of alternative techniques in improving outcomes. Despite the predominance of standard sites due to their proven efficacy, the heterogeneity of patient conditions underscores the need for flexible, patient-tailored approaches.
- 27 July 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 62 (3)
Obesity and outcomes after left ventricular assist device implantation: insights from the EUROMACS Registry
The objective was to analyze associations between obesity and outcomes after left ventricular assist device implantation. A retrospective analysis of the EUROMACS Registry was performed. Adult patients undergoing primary implantation of a continuous-flow left ventricular assist device between 2006 and 2019 were included (Medtronic HeartWare® HVAD®, Abbott HeartMate II®, Abbott HeartMate 3™). Patients were classified in 4 different groups according to body mass index at the time of surgery (body mass index < 20 kg/m2: n = 254; 20–24.9 kg/m2: n = 1281; 25–29.9 kg/m2: n = 1238; ≥ 30 kg/m2: n = 691). The study cohort was comprised of 3464 patients. Multivariable Cox proportional cause-specific hazards regression analysis demonstrated that obesity (body mass index ≥ 30 kg/m2) was independently associated with significantly increased risk of mortality (body mass index “≥ 30” vs “20–24.9” kg/m2: hazard ratio 1.36, 95% confidence interval 1.18 to 1.57, overall p < 0.001). Moreover, obesity was associated with significantly increased risk of infection and driveline infection. The probability to undergo heart transplantation was significantly decreased in obese patients (body mass index “≥ 30” vs “20–24.9” kg/m2: hazard ratio 0.59, 95% confidence interval 0.48 to 0.74, overall p < 0.001). Obesity at the time of left ventricular assist device implantation is associated with significantly higher mortality and increased risk of infection as well as driveline infection. The probability to undergo heart transplantation is significantly decreased. These aspects should be considered when devising a treatment strategy before surgery.
- 27 July 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 62 (3)
Obesity and outcomes after left ventricular assist device implantation: insights from the EUROMACS Registry
The objective was to analyze associations between obesity and outcomes after left ventricular assist device implantation. A retrospective analysis of the EUROMACS Registry was performed. Adult patients undergoing primary implantation of a continuous-flow left ventricular assist device between 2006 and 2019 were included (Medtronic HeartWare® HVAD®, Abbott HeartMate II®, Abbott HeartMate 3™). Patients were classified in 4 different groups according to body mass index at the time of surgery (body mass index < 20 kg/m2: n = 254; 20–24.9 kg/m2: n = 1281; 25–29.9 kg/m2: n = 1238; ≥ 30 kg/m2: n = 691). The study cohort was comprised of 3464 patients. Multivariable Cox proportional cause-specific hazards regression analysis demonstrated that obesity (body mass index ≥ 30 kg/m2) was independently associated with significantly increased risk of mortality (body mass index “≥ 30” vs “20–24.9” kg/m2: hazard ratio 1.36, 95% confidence interval 1.18 to 1.57, overall p < 0.001). Moreover, obesity was associated with significantly increased risk of infection and driveline infection. The probability to undergo heart transplantation was significantly decreased in obese patients (body mass index “≥ 30” vs “20–24.9” kg/m2: hazard ratio 0.59, 95% confidence interval 0.48 to 0.74, overall p < 0.001). Obesity at the time of left ventricular assist device implantation is associated with significantly higher mortality and increased risk of infection as well as driveline infection. The probability to undergo heart transplantation is significantly decreased. These aspects should be considered when devising a treatment strategy before surgery.
- 21 July 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (12) , 1850-1857
The effect of occlusive polytetrafluoroethylene outflow graft protectors in left ventricular assist device recipients
- 21 July 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (12) , 1850-1857
The effect of occlusive polytetrafluoroethylene outflow graft protectors in left ventricular assist device recipients
- Open Access
Validation of Intrinsic Left Ventricular Assist Device Data Tracking Algorithm for Early Recognition of Centrifugal Flow Pump Thrombosis
Advanced stage heart failure patients can benefit from the unloading effects of an implantable left ventricular assist device. Despite best clinical practice, LVADs are associated with adverse events, such as pump thrombosis (PT). An adaptive algorithm alerting when an individual’s appropriate levels in pump power uptake are exceeded, such as in the case of PT, can improve therapy of patients implanted with a centrifugal LVAD. We retrospectively studied 75 patients implanted with a centrifugal LVAD in a single center. A previously optimized adaptive pump power-tracking algorithm was compared to clinical best practice and clinically available constant threshold algorithms. Algorithm performances were analyzed in a PT group (n = 16 patients with 30 PT events) and a thoroughly selected control group (n = 59 patients, 34.7 patient years of LVAD data). Comparison of the adaptive power-tracking algorithm with the best performing constant threshold algorithm resulted in sensitivity of 83.3% vs. 86.7% and specificity of 98.9% vs. 95.3%, respectively. The power-tracking algorithm produced one false positive detection every 11.6 patient years and early warnings with a median of 3.6 days prior to PT diagnosis. In conclusion, a retrospective single-center validation study with real-world patient data demonstrated advantageous application of a power-tracking algorithm into LVAD systems and clinical practice.
Open AccessValidation of Intrinsic Left Ventricular Assist Device Data Tracking Algorithm for Early Recognition of Centrifugal Flow Pump Thrombosis
Advanced stage heart failure patients can benefit from the unloading effects of an implantable left ventricular assist device. Despite best clinical practice, LVADs are associated with adverse events, such as pump thrombosis (PT). An adaptive algorithm alerting when an individual’s appropriate levels in pump power uptake are exceeded, such as in the case of PT, can improve therapy of patients implanted with a centrifugal LVAD. We retrospectively studied 75 patients implanted with a centrifugal LVAD in a single center. A previously optimized adaptive pump power-tracking algorithm was compared to clinical best practice and clinically available constant threshold algorithms. Algorithm performances were analyzed in a PT group (n = 16 patients with 30 PT events) and a thoroughly selected control group (n = 59 patients, 34.7 patient years of LVAD data). Comparison of the adaptive power-tracking algorithm with the best performing constant threshold algorithm resulted in sensitivity of 83.3% vs. 86.7% and specificity of 98.9% vs. 95.3%, respectively. The power-tracking algorithm produced one false positive detection every 11.6 patient years and early warnings with a median of 3.6 days prior to PT diagnosis. In conclusion, a retrospective single-center validation study with real-world patient data demonstrated advantageous application of a power-tracking algorithm into LVAD systems and clinical practice.
- Open Access
- 24 February 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 61 (6) , 1438-1439
The bittersweet consequences of diabetes on mortality following left ventricular assist device implantation
- 24 February 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 61 (6) , 1438-1439
Open AccessThe bittersweet consequences of diabetes on mortality following left ventricular assist device implantation
- 1 September 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 61 (3) , 716-724
Incidence, clinical relevance and therapeutic options for outflow graft stenosis in patients with left ventricular assist devices
We reviewed our institutional experience with outflow graft stenosis (OGS) in 3 contemporary left ventricular assist devices (LVAD). Data from 347 consecutive adult recipients of LVAD [Medtronic HVAD (n = 184, 53.0%), Abbott HeartMate II (n = 62, 17.9%) and Abbott HeartMate 3 (n = 101, 29.1%)] implanted between March 2006 and October 2019 were analysed retrospectively. Primary study end points were the incidence of OGS necessitating treatment and survival on LVAD support. During the study period, 17 patients (4.9%) developed OGS requiring treatment with a probability of 0.6% at 1 year, 1.9% at 2 years, 3.8% at 3 years, 4.7% at 4 years and 5.9% at 5 years of LVAD support. Notably, in 13.8% of patients, a compression-related narrowing of the outflow graft with a probability of 1.5% at 6 months, 1.8% 1 year, 6.0% at 2 years, 12.3% at 3 years, 15.4% at 4 years and 16.6% at 5 years of LVAD support with no difference between devices (P = 0.26) was observed. There was a trend towards increased risk of mortality with OGS (hazard ratio 2.21, 95% confidence interval 0.87–5.51; P = 0.09). OGS preferentially occurred in segments of the outflow graft covered by a protective coating. OGS is a rare but potentially lethal complication during LVAD support. Modifications of pump design and implant techniques may be needed because OGS preferentially occurs within covered portions of the outflow graft. Systematic screening may be warranted.
- 1 September 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 61 (3) , 716-724
Incidence, clinical relevance and therapeutic options for outflow graft stenosis in patients with left ventricular assist devices
We reviewed our institutional experience with outflow graft stenosis (OGS) in 3 contemporary left ventricular assist devices (LVAD). Data from 347 consecutive adult recipients of LVAD [Medtronic HVAD (n = 184, 53.0%), Abbott HeartMate II (n = 62, 17.9%) and Abbott HeartMate 3 (n = 101, 29.1%)] implanted between March 2006 and October 2019 were analysed retrospectively. Primary study end points were the incidence of OGS necessitating treatment and survival on LVAD support. During the study period, 17 patients (4.9%) developed OGS requiring treatment with a probability of 0.6% at 1 year, 1.9% at 2 years, 3.8% at 3 years, 4.7% at 4 years and 5.9% at 5 years of LVAD support. Notably, in 13.8% of patients, a compression-related narrowing of the outflow graft with a probability of 1.5% at 6 months, 1.8% 1 year, 6.0% at 2 years, 12.3% at 3 years, 15.4% at 4 years and 16.6% at 5 years of LVAD support with no difference between devices (P = 0.26) was observed. There was a trend towards increased risk of mortality with OGS (hazard ratio 2.21, 95% confidence interval 0.87–5.51; P = 0.09). OGS preferentially occurred in segments of the outflow graft covered by a protective coating. OGS is a rare but potentially lethal complication during LVAD support. Modifications of pump design and implant techniques may be needed because OGS preferentially occurs within covered portions of the outflow graft. Systematic screening may be warranted.
- Open Access
- 1 January 2017
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 65 (S 01) , S1-S110
Micro-Embolic Signals Correlate with Pump Thrombus Formation and Non-Thrombotic Outflow Graft Occlusion in Patients with Left Ventricular Assist Devices
Objectives: Micro-emboli are detectable as high intensity transient signals (HITS) with Doppler ultrasound in different clinical conditions including patients with left ventricular assist devices (LVAD). In LVAD patients HITS represent micro-emboli of mostly gaseous nature. The cause of their formation, however, has not been determined. Methods: From June 2014 to September 2016 LVAD patients were systematically screed for HITS in the LVAD outflow graft by transthoracic echocardiography. The occurrence of HITS was then correlated with pump thrombus formation (PT) and non-thrombotic outflow graft occlusion. Results: HITS were detected in the outflow graft of 20 LVAD patients (Thoratec Heartmate II n = 12, Heartware HVAD n = 8). HITS correlated with PT in 14 patients (Heartmate II n = 7, HVAD n = 7) and non-thrombotic outflow graft stenosis in 6 patients (Heartmate II n = 5, HVAD n = 1). Patients with PT either underwent thrombolysis (n = 7), pump exchange (n = 2), LVAD weaning (n = 1) or no treatment if no hard clinical treatment indication was present (n = 5). In PT patients HITS disappeared after successful thrombolysis or pump exchange. Of note, pump thrombus formation or non-thrombotic outflow graft stenosis could be macroscopically assured at the time of transplant in the remaining patients. Conclusion: HITS detection by transthoracic echocardiography identifies patients with pump thrombus formation and non-thrombotic outflow graft occlusion and might develop as a very sensitive screening tool for pump pathology and hypocoagulation monitoring.
- 1 January 2017
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 65 (S 01) , S1-S110
Open AccessMicro-Embolic Signals Correlate with Pump Thrombus Formation and Non-Thrombotic Outflow Graft Occlusion in Patients with Left Ventricular Assist Devices
Objectives: Micro-emboli are detectable as high intensity transient signals (HITS) with Doppler ultrasound in different clinical conditions including patients with left ventricular assist devices (LVAD). In LVAD patients HITS represent micro-emboli of mostly gaseous nature. The cause of their formation, however, has not been determined. Methods: From June 2014 to September 2016 LVAD patients were systematically screed for HITS in the LVAD outflow graft by transthoracic echocardiography. The occurrence of HITS was then correlated with pump thrombus formation (PT) and non-thrombotic outflow graft occlusion. Results: HITS were detected in the outflow graft of 20 LVAD patients (Thoratec Heartmate II n = 12, Heartware HVAD n = 8). HITS correlated with PT in 14 patients (Heartmate II n = 7, HVAD n = 7) and non-thrombotic outflow graft stenosis in 6 patients (Heartmate II n = 5, HVAD n = 1). Patients with PT either underwent thrombolysis (n = 7), pump exchange (n = 2), LVAD weaning (n = 1) or no treatment if no hard clinical treatment indication was present (n = 5). In PT patients HITS disappeared after successful thrombolysis or pump exchange. Of note, pump thrombus formation or non-thrombotic outflow graft stenosis could be macroscopically assured at the time of transplant in the remaining patients. Conclusion: HITS detection by transthoracic echocardiography identifies patients with pump thrombus formation and non-thrombotic outflow graft occlusion and might develop as a very sensitive screening tool for pump pathology and hypocoagulation monitoring.